---
title: "Bide Pharmaceuticals released its first-quarter performance, with a net profit attributable to the parent company of 30.69 million yuan, a year-on-year increase of 17.71%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237209047.md"
description: "According to the Zhitong Finance APP, Bide Pharmaceuticals disclosed its first-quarter report for 2025, reporting revenue of 296 million yuan, a year-on-year increase of 12.83%; net profit attributable to the parent company of 30.69 million yuan, a year-on-year increase of 17.71%; and net profit excluding non-recurring items of 28.08 million yuan, a year-on-year increase of 10.40%. Basic earnings per share were 0.34 yuan"
datetime: "2025-04-23T14:38:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237209047.md)
  - [en](https://longbridge.com/en/news/237209047.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237209047.md)
generator: "portal-rs"
---

# Bide Pharmaceuticals released its first-quarter performance, with a net profit attributable to the parent company of 30.69 million yuan, a year-on-year increase of 17.71%

According to the Zhitong Finance APP, Bide (688073.SH) disclosed its first-quarter report for 2025, showing that the company achieved revenue of 296 million yuan during the reporting period, a year-on-year increase of 12.83%; net profit attributable to the parent company was 30.69 million yuan, a year-on-year increase of 17.71%; and net profit excluding non-recurring items was 28.08 million yuan, a year-on-year increase of 10.40%. The basic earnings per share were 0.34 yuan

### Related Stocks

- [688073.CN](https://longbridge.com/en/quote/688073.CN.md)

## Related News & Research

- [WUXI APPTEC  Sells 4.23% Stake in WUXI XDC, Cashes In HKD3.9B](https://longbridge.com/en/news/297217460.md)
- [Axie Infinity to Hold Hackathon on September 1st](https://longbridge.com/en/news/297359940.md)
- [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md)
- [Grayscale Bittensor Trust issues 296,200 shares in private placement for $1.31 million](https://longbridge.com/en/news/297226943.md)
- [ByHeart Says FDA Confirms Review Of ByHeart's Root Cause Investigation And Action Plan](https://longbridge.com/en/news/297358769.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**